Abstract
4015 Background: The incidence of esophageal adenocarcinoma (EAC) has increased 6-fold in the last 30 years and in early stage EAC 5-year survival remains poor at 25-35%. Neoadjuvant therapy confer...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have